Salvage radiotherapy following radical prostatectomy

International Journal of Urology

Volumn 16, Issue 1, 2009, Pages 31-36

  Chalasani, Venu ^a   Iansavichene, Alla E ^a   Lock, Michael ^a   Izawa, Jonathan I ^a,b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Prostate specific antigen failure; Prostatectomy; Prostatic neoplasms; Radiotherapy; Recurrence; Salvage therapy

Indexed keywords

DOCETAXEL; GOSERELIN; PROSTATE SPECIFIC ANTIGEN;

CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; GASTROINTESTINAL TOXICITY; GLEASON SCORE; HUMAN; LYMPH NODE METASTASIS; MORBIDITY; NOMOGRAM; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; PROTEIN BLOOD LEVEL; RADIATION DOSE; REVIEW; SALVAGE THERAPY; TREATMENT RESPONSE; UROGENITAL TRACT DISEASE;

HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; NOMOGRAMS; PATIENT SELECTION; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIATION DOSAGE; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; SALVAGE THERAPY;

EID: 58149202487     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2008.02144.x     Document Type: Review

References (89)

1. Miller DC, Gruber SB, Hollenbeck BK, Montie JE, Wei JT. Incidence of initial local therapy among men with lower-risk prostate cancer in the united states. J. Natl. Cancer Inst. 2006 98 : 1134 41.
2. Amling CL, Blute ML, Bergstralh EJ, Seay TM, Slezak J, Zincke H. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J. Urol. 2000 164 : 101 5.
3. Chun FK, Graefen M, Zacharias M et al. Anatomic radical retropubic prostatectomy-long-term recurrence-free survival rates for localized prostate cancer. World J. Urol. 2006 24 : 273 80.
4. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy: the 15-year johns hopkins experience. Urol. Clin. North Am. 2001 28 : 555 65.
5. Bianco FJ Jr., Scardino PT, Eastham JA. Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function ('trifecta'). Urology 2005 66 : 83 94.
6. Hayashi M, Shinmei S, Asano K. Transrectal high-intensity focused ultrasound for treatment for patients with biochemical failure after radical prostatectomy. Int. J. Urol. 2007 14 : 1048 50.
7. Duchesne GM, Millar JL, Moraga V, Rosenthal M, Royce P, Snow R. What to do for prostate cancer patients with a rising PSA? - a survey of Australian practice. Int. J. Radiat. Oncol. Biol. Phys. 2003 55 : 986 91.
8. Mehta SS, Lubeck DP, Sadetsky N, Pasta DJ, Carroll PR. Patterns of secondary cancer treatment for biochemical failure following radical prostatectomy: data from CaPSURE. J. Urol. 2004 171 : 215 19.
9. Stephenson AJ, Scardino PT, Kattan MW et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J. Clin. Oncol. 2007 25 : 2035 41.
10. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999 281 : 1591 7.
11. Zincke H, Oesterling JE, Blute ML, Bergstralh EJ, Myers RP, Barrett DM. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J. Urol. 1994 152 : 1850 7.
12. Freedland SJ, Humphreys EB, Mangold LA et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005 294 : 433 9.
13. Sandler HM, Eisenberger MA. Assessing and treating patients with increasing prostate specific antigen following radical prostatectomy. J.Urol. 2007 178 : S20 4.
14. Kamidono S, Ohshima S, Hirao Y et al Working Group for Creation of Clinical Practice Guidelines For Prostate Cancer, The Japanese Urological Association). Evidence-based clinical practice guidelines for prostate cancer (summary - JUA 2006 edition). Int. J. Urol. 2008 15 : 1 18.
15. Cher ML, Bianco FJ Jr., Lam JS et al. Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J. Urol. 1998 160 : 1387 91.
16. Kane CJ, Amling CL, Johnstone PA et al. Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology 2003 61 : 607 11.
17. Lawrentschuk N, Davis ID, Bolton DM, Scott AM. Diagnostic and therapeutic use of radioisotopes for bony disease in prostate cancer: current practice. Int. J. Urol. 2007 14 : 89 95.
18. Proano JM, Sodee DB, Resnick MI, Einstein DB. The impact of a negative (111)indium-capromab pendetide scan before salvage radiotherapy. J. Urol. 2006 175 : 1668 72.
19. Koontz BF, Mouraviev V, Johnson JL et al. Use of local (111)in-capromab pendetide scan results to predict outcome after salvage radiotherapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2008 71 : 358 61.
20. Nagda SN, Mohideen N, Lo SS et al. Long-term follow-up of 111In-capromab pendetide (ProstaScint) scan as pretreatment assessment in patients who undergo salvage radiotherapy for rising prostate-specific antigen after radical prostatectomy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2007 67 : 834 40.
21. Pisansky TM, Kozelsky TF, Myers RP et al. Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer. J. Urol. 2000 163 : 845 50.
22. Stephenson AJ, Slawin KM. The value of radiotherapy in treating recurrent prostate cancer after radical prostatectomy. Nat. Clin. Pract. Urol. 2004 1 : 90 6.
23. Cheung R, Kamat AM, de Crevoisier R et al. Outcome of salvage radiotherapy for biochemical failure after radical prostatectomy with or without hormonal therapy. Int. J. Radiat. Oncol. Biol. Phys. 2005 63 : 134 40.
24. Hayes SB, Pollack A. Parameters for treatment decisions for salvage radiation therapy. J. Clin. Oncol. 2005 23 : 8204 11.
25. Buskirk SJ, Pisansky TM, Schild SE et al. Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: evaluation of prognostic factors and creation of a prognostic scoring system. J. Urol. 2006 176 : 985 90.
26. Stephenson AJ, Shariat SF, Zelefsky MJ et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 2004 291 : 1325 32.
27. Jereczek-Fossa BA, Orecchia R. Evidence-based radiation oncology: definitive, adjuvant and salvage radiotherapy for non-metastatic prostate cancer. Radiother. Oncol. 2007 84 : 197 215.
28. Neuhof D, Hentschel T, Bischof M, Sroka-Perez G, Hohenfellner M, Debus J. Long-term results and predictive factors of three-dimensional conformal salvage radiotherapy for biochemical relapse after prostatectomy. Int. J. Radiat. Oncol. Biol. Phys. 2007 67 : 1411 17.
29. MacDonald OK, Schild SE, Vora S et al. Salvage radiotherapy for men with isolated rising PSA or locally palpable recurrence after radical prostatectomy: do outcomes differ? Urology 2004 64 : 760 4.
30. Anscher MS, Clough R, Dodge R. Radiotherapy for a rising prostate-specific antigen after radical prostatectomy: the first 10 years. Int. J. Radiat. Oncol. Biol. Phys. 2000 48 : 369 75.
31. Cadeddu JA, Partin AW, DeWeese TL, Walsh PC. Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy. J. Urol. 1998 159 : 173 7 discussion 177 8.
32. Do LV, Do TM, Smith R, Parker RG. Postoperative radiotherapy for carcinoma of the prostate: impact on both local control and distant disease-free survival. Am. J. Clin. Oncol. 2002 25 : 1 8.
33. Taylor N, Kelly JF, Kuban DA, Babaian RJ, Pisters LL, Pollack A. Adjuvant and salvage radiotherapy after radical prostatectomy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2003 56 : 755 63.
34. Nudell DM, Grossfeld GD, Weinberg VK, Roach M 3rd., Carroll PR. Radiotherapy after radical prostatectomy: treatment outcomes and failure patterns. Urology 1999 54 : 1049 57.
35. Peyromaure M, Allouch M, Eschwege F, Verpillat P, Debre B, Zerbib M. Salvage radiotherapy for biochemical recurrence after radical prostatectomy: a study of 62 patients. Urology 2003 62 : 503 7.
36. Song DY, Thompson TL, Ramakrishnan V et al. Salvage radiotherapy for rising or persistent PSA after radical prostatectomy. Urology 2002 60 : 281 7.
37. Quero L, Mongiat-Artus P, Ravery V, Maylin C, Desgrandchamps F, Hennequin C. Salvage radiotherapy for patients with PSA relapse after radical prostatectomy: a single institution experience. BMC Cancer. 2008 8 : 26.
38. Chawla AK, Thakral HK, Zietman AL, Shipley WU. Salvage radiotherapy after radical prostatectomy for prostate adenocarcinoma: analysis of efficacy and prognostic factors. Urology 2002 59 : 726 31.
39. Vanuytsel L, Janssens G, Van Poppel H, Rijnders A, Baert L. Radiotherapy for PSA recurrence after radical prostatectomy. Eur. Urol. 2001 39 : 425 9.
40. de la Taille A, Flam TA, Thiounn N et al. Predictive factors of radiation therapy for patients with prostate specific antigen recurrence after radical prostatectomy. BJU Int. 2002 90 : 887 92.
41. Liauw SL, Webster WS, Pistenmaa DA, Roehrborn CG. Salvage radiotherapy for biochemical failure of radical prostatectomy: a single-institution experience. Urology 2003 61 : 1204 10.
42. Leventis AK, Shariat SF, Kattan MW, Butler EB, Wheeler TM, Slawin KM. Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. J. Clin. Oncol. 2001 19 : 1030 9.
43. Morris MM, Dallow KC, Zietman AL et al. Adjuvant and salvage irradiation following radical prostatectomy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 1997 38 : 731 6.
44. Kalapurakal JA, Huang CF, Neriamparampil MM et al. Biochemical disease-free survival following adjuvant and salvage irradiation after radical prostatectomy. Int. J. Radiat. Oncol. Biol. Phys. 2002 54 : 1047 54.
45. Stockdale AD, Vakkalanka BK, Fahmy A, Desai K, Blacklock AR. Management of biochemical failure following radical prostatectomy: salvage radiotherapy - a case series. Prostate Cancer Prostatic Dis. 2007 10 : 205 9.
46. Vicini FA, Ziaja EL, Kestin LL et al. Treatment outcome with adjuvant and salvage irradiation after radical prostatectomy for prostate cancer. Urology 1999 54 : 111 17.
47. Lange PH, Lightner DJ, Medini E, Reddy PK, Vessella RL. The effect of radiation therapy after radical prostatectomy in patients with elevated prostate specific antigen levels. J. Urol. 1990 144 : 927 32 discussion 932 3.
48. Kaplan ID, Bagshaw MA. Serum prostate-specific antigen after post-prostatectomy radiotherapy. Urology 1992 39 : 401 6.
49. Wiegel T, Bressel M, Arps H, Hubener KH. Radiotherapy of local recurrence following radical prostatectomy. Strahlenther. Onkol. 1992 168 : 333 6.
50. Haab F, Meulemans A, Boccon-Gibod L et al. Effect of radiation therapy after radical prostatectomy on serum prostate-specific antigen measured by an ultrasensitive assay. Urology 1995 45 : 1022 7.
51. Medini E, Medini I, Reddy PK, Levitt SH. Delayed/salvage radiation therapy in patients with elevated prostate specific antigen levels after radical prostatectomy. A long term follow-up. Cancer 1996 78 : 1254 9.
52. Crane CH, Rich TA, Read PW, Sanfilippo NJ, Gillenwater JY, Kelly MD. Preirradiation PSA predicts biochemical disease-free survival in patients treated with postprostatectomy external beam irradiation. Int. J. Radiat. Oncol. Biol. Phys. 1997 39 : 681 6.
53. Rogers R, Grossfeld GD, Roach M 3rd., Shinohara K, Presti JC Jr., Carroll PR. Radiation therapy for the management of biopsy proved local recurrence after radical prostatectomy. J. Urol. 1998 160 : 1748 53.
54. Garg MK, Tekyi-Mensah S, Bolton S et al. Impact of postprostatectomy prostate-specific antigen nadir on outcomes following salvage radiotherapy. Urology 1998 51 : 998 1002.
55. Peschel RE, Robnett TJ, Hesse D et al. PSA based review of adjuvant and salvage radiation therapy vs. observation in postoperative prostate cancer patients. Int. J. Cancer 2000 90 : 29 36.
56. Catton C, Gospodarowicz M, Warde P et al. Adjuvant and salvage radiation therapy after radical prostatectomy for adenocarcinoma of the prostate. Radiother. Oncol. 2001 59 : 51 60.
57. Mayer R, Pummer K, Quehenberger F, Mayer E, Fink L, Hackl A. Postprostatectomy radiotherapy for high-risk prostate cancer. Urology 2002 59 : 732 9.
58. Choo R, Hruby G, Hong J et al IN)-efficacy of salvage radiotherapy for rising PSA or clinically isolated local recurrence after radical prostatectomy. Int. J. Radiat. Oncol. Biol. Phys. 2002 53 : 269 76.
59. Schwarz R, Krull A, Tribius S, Alberti W. Results of three dimensional conformal radiotherapy and hormonal therapy for local recurrence after radical prostatectomy. Strahlenther. Onkol. 2005 181 : 442 7.
60. Jung C, Cookson MS, Chang SS, Smith JA Jr., Dietrich MS, Teng M. Toxicity following high-dose salvage radiotherapy after radical prostatectomy. BJU Int. 2007 99 : 529 33.
61. Feng M, Hanlon AL, Pisansky TM et al. Predictive factors for late genitourinary and gastrointestinal toxicity in patients with prostate cancer treated with adjuvant or salvage radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2007 68 : 1417 23.
62. Parker C, Warde P, Catton C. Salvage radiotherapy for PSA failure after radical prostatectomy. Radiother. Oncol. 2001 61 : 107 16.
63. Jani AB, Kao J. Postprostatectomy adjuvant versus salvage radiotherapy: a complication-adjusted number-needed-to-treat analysis. Cancer 2005 103 : 1833 42.
64. Schwarz R, Graefen M, Krull A. Therapy of recurrent disease after radical prostatectomy in 2007. World J. Urol. 2007 25 : 161 7.
65. Zelefsky MJ, Aschkenasy E, Kelsen S, Leibel SA. Tolerance and early outcome results of postprostatectomy three-dimensional conformal radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 1997 39 : 327 33.
66. vander Kooy MJ, Pisansky TM, Cha SS, Blute ML. Irradiation for locally recurrent carcinoma of the prostate following radical prostatectomy. Urology 1997 49 : 65 70.
67. Petrovich Z, Lieskovsky G, Langholz B et al. Radical prostatectomy and postoperative irradiation in patients with pathological stage C (T3) carcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys. 1998 40 : 139 47.
68. Do T, Parker RG, Do C, Tran L, Do L, Dolkar D. Salvage radiotherapy for biochemical and clinical failures following radical prostatectomy. Cancer J. Sci. Am. 1998 4 : 324 30.
69. Valicenti RK, Gomella LG, Ismail M, Mulholland SG, Petersen RO, Corn BW. Effect of higher radiation dose on biochemical control after radical prostatectomy for PT3N0 prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 1998 42 : 501 6.
70. Forman JD, Velasco J. Therapeutic radiation in patients with a rising post-prostatectomy PSA level. Oncology (Williston Park) 1998 12 : 33 9 discussion 39, 43 4, 47.
71. Raymond JF, Vuong M, Russell KJ. Neutron beam radiotherapy for recurrent prostate cancer following radical prostatectomy. Int. J. Radiat. Oncol. Biol. Phys. 1998 41 : 93 9.
72. Egawa S, Ohori M, Iwamura M, Kuwao S, Baba S. Efficacy and limitations of delayed/salvage radiation therapy after radical prostatectomy. BJU Int. 1999 84 : 815 20.
73. Wilder RB, Hsiang JY, Ji M, Earle JD, de Vere White R. Preliminary results of three-dimensional conformal radiotherapy as salvage treatment for a rising prostate-specific antigen level postprostatectomy. Am. J. Clin. Oncol. 2000 23 : 176 80.
74. Choo R, Hruby G, Hong J et al. Positive resection margin and/or pathologic T3 adenocarcinoma of prostate with undetectable postoperative prostate-specific antigen after radical prostatectomy: to irradiate or not? Int. J. Radiat. Oncol. Biol. Phys. 2002 52 : 674 80.
75. Duchesne GM, Dowling C, Frydenberg M et al. Outcome, morbidity, and prognostic factors in post-prostatectomy radiotherapy: an Australian multicenter study. Urology 2003 61 : 179 83.
76. Jani AB, Blend MJ, Hamilton R et al. Radioimmunoscintigraphy for postprostatectomy radiotherapy: analysis of toxicity and biochemical control. J. Nucl. Med. 2004 45 : 1315 22.
77. Maier J, Forman J, Tekyi-Mensah S, Bolton S, Patel R, Pontes JE. Salvage radiation for a rising PSA following radical prostatectomy. Urol. Oncol. 2004 22 : 50 6.
78. Cozzarini C, Fiorino C, Ceresoli GL et al. Significant correlation between rectal DVH and late bleeding in patients treated after radical prostatectomy with conformal or conventional radiotherapy (66.6-70.2 gy). Int. J. Radiat. Oncol. Biol. Phys. 2003 55 : 688 94.
79. Namiki S, Saito S, Tochigi T, Ioritani N, Terai A, Arai Y. Impact of salvage therapy for biochemical recurrence on health-related quality of life following radical prostatectomy. Int. J. Urol. 2007 14 : 186 91.
80. Pinkawa M, Fischedick K, Asadpour B et al. Health-related quality of life after adjuvant and salvage postoperative radiotherapy for prostate cancer - a prospective analysis. Radiother. Oncol. 2008 88 : 135 9.
81. Pearce A, Choo R, Danjoux C et al. Effect of combined treatment with salvage radiotherapy plus androgen suppression on quality of life in patients with recurrent prostate cancer after radical prostatectomy. Int. J. Radiat. Oncol. Biol. Phys. 2006 65 : 78 83.
82. Tefilli MV, Gheiler EL, Tiguert R et al. Quality of life in patients undergoing salvage procedures for locally recurrent prostate cancer. J. Surg. Oncol. 1998 69 : 156 61.
83. Thompson IM Jr., Tangen CM, Paradelo J et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 2006 296 : 2329 35.
84. Bolla M, van Poppel H, Collette L et al. Postoperative radiotherapy after radical prostatectomy: a randomized controlled trial (EORTC trial 22911). Lancet 2005 366 : 572 8.
85. King CR, Spiotto MT. Improved outcomes with higher doses for salvage radiotherapy after prostatectomy. Int. J. Radiat. Oncol. Biol. Phys. 2008 71 : 23 7.
86. King CR, Kapp DS. Radiotherapy after prostatectomy: is the evidence for dose escalation out there? Int. J. Radiat. Oncol. Biol. Phys. 2008 71 : 346 50.
87. Cox JD, Gallagher MJ, Hammond EH, Kaplan RS, Schellhammer PF. Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel. J. Clin. Oncol. 1999 17 : 1155.
88. Yokomizo A, Kawamoto H, Nihei K et al. Randomized controlled trial to evaluate radiotherapy +/- endocrine therapy versus endocrine therapy alone for PSA failure after radical prostatectomy: Japan Clinical Oncology Group Study JCOG 0401. Jpn. J. Clin. Oncol. 2005 35 : 34 6.
89. Parker C, Sydes MR, Catton C et al RADICALS Trial Management Group). Radiotherapy and androgen deprivation in combination after local surgery (RADICALS): a new Medical Research Council/National Cancer Institute of Canada phase III trial of adjuvant treatment after radical prostatectomy. BJU Int. 2007 99 : 1376 9.